| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Jerome Tamburini | Q48282150 |
| Didier Bouscary | Q48282168 | ||
| Nicolas Chapuis | Q51322110 | ||
| Valérie Bardet | Q56167780 | ||
| Lise Willems | Q43144891 | ||
| P2093 | author name string | Sophie Park | |
| Pascale Cornillet-Lefebvre | |||
| Catherine Lacombe | |||
| Patrick Mayeux | |||
| Alexa Green | |||
| P2860 | cites work | Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity | Q47634506 |
| Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2 | Q21145847 | ||
| Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex | Q24295120 | ||
| DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival | Q24311448 | ||
| mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1) | Q24324148 | ||
| A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling | Q24599676 | ||
| Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance | Q24645668 | ||
| AKT/PKB signaling: navigating downstream | Q24657857 | ||
| Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition | Q27641764 | ||
| A transforming mutation in the pleckstrin homology domain of AKT1 in cancer | Q27646556 | ||
| NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. | Q27851451 | ||
| Gab2 is involved in differential phosphoinositide 3-kinase signaling by two splice forms of c-Kit | Q28115545 | ||
| TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling | Q28131740 | ||
| Signalling through phosphoinositide 3-kinases: the lipids take centre stage | Q28141934 | ||
| PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth | Q28243336 | ||
| Rheb binds and regulates the mTOR kinase | Q28247033 | ||
| Protein kinase B (c-akt) regulates hematopoietic lineage choice decisions during myelopoiesis. | Q50886883 | ||
| A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemia. | Q51289441 | ||
| Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. | Q52576345 | ||
| Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. | Q53334759 | ||
| Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. | Q53526869 | ||
| The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion | Q56995355 | ||
| Essential role for the p110 isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia | Q57220263 | ||
| PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention | Q59067116 | ||
| Phosphatase and tensin homologue phosphorylation in the C-terminal regulatory domain is frequently observed in acute myeloid leukaemia and associated with poor clinical outcome | Q73701961 | ||
| Increased IkappaB kinase activity is associated with activated NF-kappaB in acute myeloid blasts | Q78306906 | ||
| [The PI3K/Akt/mTOR pathway: a new therapeutic target in the treatment of acute myeloid leukemia] | Q79733072 | ||
| Why is clinical progress in acute myelogenous leukemia so slow? | Q80877539 | ||
| Assessment of somatic mutations in phosphatidylinositol 3-kinase gene in human lymphoma and acute leukaemia | Q81352970 | ||
| Hsp90-Akt phosphorylates ASK1 and inhibits ASK1-mediated apoptosis | Q81554305 | ||
| Constitutive phosphoinositide 3-kinase activation in acute myeloid leukemia is not due to p110delta mutations | Q81600832 | ||
| A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16 | Q83350735 | ||
| Single cell analysis of phosphoinositide 3-kinase/Akt and ERK activation in acute myeloid leukemia by flow cytometry | Q83977171 | ||
| Targeted therapies in myeloid leukemias | Q95761695 | ||
| Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1 | Q28276788 | ||
| mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events | Q28281590 | ||
| Essential role for the p110delta phosphoinositide 3-kinase in the allergic response | Q28288981 | ||
| Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB | Q28306356 | ||
| The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins | Q28507365 | ||
| Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN | Q28513537 | ||
| Patterns of somatic mutation in human cancer genomes | Q29547841 | ||
| An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1 | Q29614563 | ||
| PI3K pathway alterations in cancer: variations on a theme | Q29615530 | ||
| FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress | Q29615562 | ||
| Targeting the phosphoinositide 3-kinase pathway in cancer | Q29615809 | ||
| Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells | Q29616552 | ||
| Targeting PI3K signalling in cancer: opportunities, challenges and limitations | Q29617685 | ||
| Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity | Q29618117 | ||
| FOXO transcription factors at the interface between longevity and tumor suppression | Q29620472 | ||
| Regulation of p110delta PI 3-kinase gene expression | Q33428537 | ||
| Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody | Q33707416 | ||
| Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase | Q34335162 | ||
| Preferential induction of apoptosis for primary human leukemic stem cells | Q34415832 | ||
| Molecular genetics of human leukemias: new insights into therapy | Q34529306 | ||
| Antigen receptor signalling: a distinctive role for the p110delta isoform of PI3K. | Q34598995 | ||
| eIF-4E expression and its role in malignancies and metastases. | Q35750118 | ||
| Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. | Q35751042 | ||
| The development of phosphatidylinositol ether lipid analogues as inhibitors of the serine/threonine kinase, Akt. | Q35814450 | ||
| mTOR regulates cell survival after etoposide treatment in primary AML cells | Q35848196 | ||
| Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial | Q35849547 | ||
| Identification of a tumour suppressor network opposing nuclear Akt function | Q35991130 | ||
| mTOR, a new therapeutic target in acute myeloid leukemia | Q36276756 | ||
| The molecular pathogenesis of acute myeloid leukemia | Q36291201 | ||
| Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. | Q36470315 | ||
| Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells | Q36508937 | ||
| Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells | Q36573268 | ||
| Signalling through Class I PI3Ks in mammalian cells | Q36628574 | ||
| The leukemic stem cell | Q36750614 | ||
| TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species | Q36916367 | ||
| mTORC1-dependent and -independent regulation of stem cell renewal, differentiation, and mobilization | Q36995422 | ||
| LKB1 is necessary for Akt-mediated phosphorylation of proapoptotic proteins | Q36999520 | ||
| Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells | Q37001645 | ||
| Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. | Q37109227 | ||
| Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR) | Q37257487 | ||
| The leukemic stem cell niche: current concepts and therapeutic opportunities | Q37295129 | ||
| FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. | Q37495206 | ||
| Autocrine pathway of angiopoietins-Tie2 system in AML cells: association with phosphatidyl-inositol 3 kinase | Q38338053 | ||
| Insulin receptor substrate-2 mediated insulin-like growth factor-I receptor overexpression in pancreatic adenocarcinoma through protein kinase Cdelta | Q39887874 | ||
| The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit. | Q39909957 | ||
| A critical role for Lyn in acute myeloid leukemia. | Q40040911 | ||
| Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38. | Q40054340 | ||
| Phosphatidylinositol ether lipid analogues that inhibit AKT also independently activate the stress kinase, p38alpha, through MKK3/6-independent and -dependent mechanisms. | Q40107095 | ||
| Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway | Q40117414 | ||
| AS602868, a dual inhibitor of IKK2 and FLT3 to target AML cells | Q40165143 | ||
| Searching for leukemia stem cells--not yet the end of the road? | Q40219645 | ||
| Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia | Q40296363 | ||
| Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway | Q40417386 | ||
| Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. | Q40498632 | ||
| Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells | Q40548220 | ||
| PI3K/AKT pathway activation in acute myeloid leukaemias is not associated with AKT1 pleckstrin homology domain mutation | Q41834152 | ||
| A novel role for Lef-1, a central transcription mediator of Wnt signaling, in leukemogenesis | Q41931798 | ||
| Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation | Q42448479 | ||
| Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis | Q42467738 | ||
| Constitutive phosphorylation of the S6 ribosomal protein via mTOR and ERK signaling in the peripheral blasts of acute leukemia patients | Q42500588 | ||
| Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia | Q42742064 | ||
| The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia. | Q43515530 | ||
| Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells | Q43757315 | ||
| Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). | Q43919081 | ||
| Activation of phosphatidylinositol 3-kinase is important for erythropoietin-induced erythropoiesis from CD34(+) hematopoietic progenitor cells | Q44133598 | ||
| Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation. | Q44265467 | ||
| Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia | Q44279382 | ||
| Survival of acute myeloid leukemia cells requires PI3 kinase activation | Q44408364 | ||
| Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable | Q44443469 | ||
| Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia | Q44536202 | ||
| FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins | Q44775125 | ||
| Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. | Q44901078 | ||
| Antileukemic activity of rapamycin in acute myeloid leukemia. | Q45154681 | ||
| Small-molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells | Q45228618 | ||
| PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways | Q45259661 | ||
| Reduced proliferation of CD34(+) cells from patients with acute myeloid leukemia after gene transfer of INPP5D. | Q45882545 | ||
| Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. | Q46003222 | ||
| Wnt signaling pathway is epigenetically regulated by methylation of Wnt antagonists in acute myeloid leukemia. | Q46040085 | ||
| PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. | Q46544691 | ||
| The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. | Q46544703 | ||
| Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells | Q46956224 | ||
| P433 | issue | 5 | |
| P921 | main subject | leukemia | Q29496 |
| P304 | page(s) | 819-828 | |
| P577 | publication date | 2009-11-30 | |
| P1433 | published in | Haematologica | Q5638209 |
| P1476 | title | Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia | |
| P478 | volume | 95 |
| Q28597169 | A Crowdsourcing Approach to Developing and Assessing Prediction Algorithms for AML Prognosis |
| Q38029572 | AKT as locus of cancer positive feedback loops and extreme robustness |
| Q34212654 | AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias |
| Q39425394 | Activation of Akt is associated with poor prognosis and chemotherapeutic resistance in pediatric B-precursor acute lymphoblastic leukemia |
| Q35031403 | Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia |
| Q58793734 | Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial |
| Q42765065 | Allogeneic stem cell transplantation for acute myeloid leukemia |
| Q33709439 | An oral quinoline derivative, MPT0B392, causes leukemic cells mitotic arrest and overcomes drug resistant cancer cells |
| Q90383801 | An updated review on activated PI3 kinase delta syndrome (APDS) |
| Q41543989 | Anti-Apoptotic Effects of Osteopontin via the Up-Regulation of AKT/mTOR/β-Catenin Loop in Acute Myeloid Leukemia Cells |
| Q43461214 | Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect |
| Q37662181 | Antineoplastic effects and mechanisms of micheliolide in acute myelogenous leukemia stem cells |
| Q35083330 | Automatic context-specific subnetwork discovery from large interaction networks |
| Q55190969 | CD300A promotes tumor progression by PECAM1, ADCY7 and AKT pathway in acute myeloid leukemia. |
| Q45997551 | CITED2 affects leukemic cell survival by interfering with p53 activation. |
| Q38742000 | Cell intrinsic and extrinsic regulation of leukemia cell metabolism |
| Q47817718 | Circulating cytokines and small molecules follow distinct expression patterns in acute myeloid leukaemia. |
| Q37377906 | Cytoplasmic localization of wild-type survivin is associated with constitutive activation of the PI3K/Akt signaling pathway and represents a favorable prognostic factor in patients with acute myeloid leukemia |
| Q38710398 | Demethoxycurcumin inhibited human epithelia ovarian cancer cells' growth via up-regulating miR-551a |
| Q33394052 | Developmental differences in megakaryocytopoiesis are associated with up-regulated TPO signaling through mTOR and elevated GATA-1 levels in neonatal megakaryocytes |
| Q26991736 | Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy |
| Q39923951 | Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients. |
| Q37235632 | Drosophila as a model for the two myeloid blood cell systems in vertebrates. |
| Q38893052 | Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110α subunit of PI3 kinase |
| Q42974476 | Effect of CAL-101, a PI3Kδ inhibitor, on ribosomal rna synthesis and cell proliferation in acute myeloid leukemia cells |
| Q46811924 | Experimentally induced, synergistic late effects of a single dose of radiation and aging: significance in LKS fraction as compared with mature blood cells |
| Q54362642 | Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis. |
| Q57470958 | GLI1 promotes cancer stemness through intracellular signaling pathway PI3K/Akt/NFκB in colorectal adenocarcinoma |
| Q50078380 | Gfi1b: a key player in the genesis and maintenance of acute myeloid leukemia and myelodysplastic syndrome |
| Q48219674 | INPP4B overexpression is associated with poor clinical outcome and therapy resistance in acute myeloid leukemia |
| Q49993172 | INPP4B promotes cell survival via SGK3 activation in NPM1-mutated leukemia |
| Q38987321 | Idarubicin induces mTOR-dependent cytotoxic autophagy in leukemic cells |
| Q37583378 | Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization |
| Q34937030 | Identification of genetic variants or genes that are associated with Homoharringtonine (HHT) response through a genome-wide association study in human lymphoblastoid cell lines (LCLs) |
| Q39326047 | Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia |
| Q36009767 | Insulin Signaling in Insulin Resistance States and Cancer: A Modeling Analysis. |
| Q37641753 | Knockdown of NEAT1 restrained the malignant progression of glioma stem cells by activating microRNA let-7e |
| Q38695065 | Knockdown of eukaryotic translation initiation factor 3 subunit D (eIF3D) inhibits proliferation of acute myeloid leukemia cells |
| Q98943915 | LINC00649 underexpression is an adverse prognostic marker in acute myeloid leukemia |
| Q38971572 | Leucine stimulates ASCT2 amino acid transporter expression in porcine jejunal epithelial cell line (IPEC-J2) through PI3K/Akt/mTOR and ERK signaling pathways |
| Q34750609 | Leukemic cell xenograft in zebrafish embryo for investigating drug efficacy. |
| Q36282427 | Lipidomic approach for stratification of acute myeloid leukemia patients |
| Q40873454 | MAT2B promotes adipogenesis by modulating SAMe levels and activating AKT/ERK pathway during porcine intramuscular preadipocyte differentiation |
| Q92890067 | Matrine induces apoptosis in acute myeloid leukemia cells by inhibiting the PI3K/Akt/mTOR signaling pathway |
| Q34442297 | Matrine induces apoptosis in human acute myeloid leukemia cells via the mitochondrial pathway and Akt inactivation |
| Q42262053 | Mesenchymal Stem Cells Support Survival and Proliferation of Primary Human Acute Myeloid Leukemia Cells through Heterogeneous Molecular Mechanisms |
| Q34071730 | MiR-223 suppresses cell proliferation by targeting IGF-1R. |
| Q52705147 | MicroRNA-185-5p restores glucocorticoid sensitivity by suppressing the mammalian target of rapamycin complex (mTORC) signaling pathway to enhance glucocorticoid receptor autoregulation. |
| Q28486136 | MicroRNAs distinguish cytogenetic subgroups in pediatric AML and contribute to complex regulatory networks in AML-relevant pathways |
| Q37643136 | Molecular therapeutic approaches for pediatric acute myeloid leukemia |
| Q34633750 | Multiple signal pathways in obesity-associated cancer |
| Q35755864 | Musashi-2 Silencing Exerts Potent Activity against Acute Myeloid Leukemia and Enhances Chemosensitivity to Daunorubicin |
| Q35102301 | Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways |
| Q36722841 | N-(2-Hydroxypropyl)methacrylamide Copolymer-Drug Conjugates for Combination Chemotherapy of Acute Myeloid Leukemia |
| Q38500371 | Novel approaches to pediatric leukemia treatment |
| Q38510486 | Novel drug therapies in myeloid leukemia |
| Q49627161 | Overexpression of Na+/Mg2+ exchanger SLC41A1 attenuates pro-survival signaling. |
| Q30499567 | Pancreatic tumor suppression by benzyl isothiocyanate is associated with inhibition of PI3K/AKT/FOXO pathway |
| Q38127844 | Perifosine--a new option in treatment of acute myeloid leukemia? |
| Q37132224 | Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells |
| Q35172210 | Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia |
| Q37046021 | Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome |
| Q92189784 | Pivotal role of mitophagy in response of acute myelogenous leukemia to a ceramide-tamoxifen-containing drug regimen |
| Q33873323 | Puquitinib, a novel orally available PI3Kδ inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemia |
| Q46393415 | Rapamycin inhibits the invasive ability of thyroid cancer cells by down-regulating the expression of VEGF-C in vitro |
| Q37811200 | Regulation and deregulation of mRNA translation during myeloid maturation |
| Q93359971 | SAMHD1 inhibits epithelial cell transformation in vitro and affects leukemia development in xenograft mice |
| Q57275043 | SAMHD1 modulates in vitro proliferation of acute myeloid leukemia-derived THP-1 cells through the PI3K-Akt-p27 axis |
| Q36688940 | SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt. |
| Q35028968 | Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes. |
| Q58767624 | Signalling mechanisms that regulate metabolic profile and autophagy of acute myeloid leukaemia cells |
| Q92366908 | Tanshinone IIA enhances the inhibitory effect of imatinib on proliferation and motility of acute leukemia cell line TIB‑152 in vivo and in vitro by inhibiting the PI3K/AKT/mTOR signaling pathway |
| Q91711797 | Targeted Therapies for Pediatric AML: Gaps and Perspective |
| Q36989223 | Targeted drug discovery for pediatric leukemia |
| Q92874380 | Targeting Metabolic Reprogramming in Acute Myeloid Leukemia |
| Q99549077 | Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence |
| Q37457673 | Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection. |
| Q36143247 | Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia. |
| Q104495182 | Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy |
| Q37122686 | Targeting survival pathways in chronic myeloid leukaemia stem cells |
| Q37591262 | Targeting the PI3K/AKT pathway via GLI1 inhibition enhanced the drug sensitivity of acute myeloid leukemia cells |
| Q35640098 | Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs |
| Q34173253 | Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway |
| Q35856790 | The Bone Marrow-Mediated Protection of Myeloproliferative Neoplastic Cells to Vorinostat and Ruxolitinib Relies on the Activation of JNK and PI3K Signalling Pathways |
| Q28074203 | The Complexity of Targeting PI3K-Akt-mTOR Signalling in Human Acute Myeloid Leukaemia: The Importance of Leukemic Cell Heterogeneity, Neighbouring Mesenchymal Stem Cells and Immunocompetent Cells |
| Q37805099 | The impact of PTEN regulation by CK2 on PI3K-dependent signaling and leukemia cell survival |
| Q33437313 | The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study |
| Q33815433 | The molecular mechanism of leptin secretion and expression induced by aristolochic acid in kidney fibroblast |
| Q35087291 | The novel arylindolylmaleimide PDA-66 displays pronounced antiproliferative effects in acute lymphoblastic leukemia cells |
| Q36379644 | The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia |
| Q39420590 | The role of sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells |
| Q37837732 | Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. |
| Q24597616 | Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na |
| Q37462530 | TrkC promotes survival and growth of leukemia cells through Akt-mTOR-dependent up-regulation of PLK-1 and Twist-1. |
| Q33710179 | Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapy |
| Q35206435 | WTAP is a novel oncogenic protein in acute myeloid leukemia |
| Q54150577 | [Effect of TSC2 gene expression downregulation by lentivirus induced RNA interference on U937 cell line and its mechanism]. |
| Q37993588 | mTOR kinase inhibitors as a treatment strategy in hematological malignancies |
Search more.